Chairs: C.N. Baxevanis (GR), M. Goulielmaki (GR)
08.40-09.00 B-cell immunity in Cancer P. Lehmann (US)
09.00-09.20 Decoding immune escape: the basis for advancing
(immuno) therapies B. Seliger (DE)
09.20-09.40 Discussion
Chairs: B. Seliger (DE), I. Nikas (CY)
10.00-10.20 Pre-existing Antitumor Immunity in NSCLC A. Xagara (GR)
10.20-10.40 Non-alcoholic steatohepatitis to hepatocellular carcinoma:
the role of inflammation Α. Chatzigeorgiou (GR)
10.40-11.00 Modulating fibroblast populations in pancreatic cancer - implications
on the immune microenvironment D. Öhlund (SE)
11.00-11.20 Discussion
Chairs: S. Karagiannis (UK), C. Gouttefangeas (DE)
11.20-11.40 Decoding the Immune Microenvironment:
Crossroads of Infection and Cancer T. Frisan (SE)
11.40-12.00 Microbiota-gut-brain axis in glioblastoma? O. Martin (FR)
12.00-12.20 Discussion
Chairs: J. Wischhusen (DE), A. Xagara (GR)
1. CONTEXT-DEPENDENT ROLE OF AUTOPHAGY IN COLORECTAL CANCER:
PROGNOSTIC SIGNIFICANCE, THERAPEUTIC IMPLICATIONS, AND CROSSTALK
WITH DRUG RESISTANCE PATHWAYS E. Koustas
2. EFFECT OF DIFFERENT CYTOKINES ON PD-L1 AND HLA-CLASS-I EXPRESSION IN
LUNG CANCER CELL LINES E. Xanthopoulou
3. EFFECT OF G-CSF ON LYMPHOCYTE COUTNS AND CD8+ LYMPHOCYTES
IN LUNG CANCER PATIENTS UNDERGOING CHEMO-RADIOTHERAPY I. Koukourakis
4. IMMUNE LANDSCAPE AND MICROBIOME-ASSOCIATED SIGNATURES IN PANCREATIC
DUCTAL ADENOCARCINOMA: INSIGHTS FROM MURINE AND ORGANOID MODELS V. Vardas
5. MECHANISTIC INSIGHTS INTO CREB1 REGULATION BY miR-128-3p IN
HER2-POSITIVE BREAST CANCER D. Kokoretsis
6. IN-DEPTH CHARACTERIZATION OF CIRCULATING EXHAUSTED AND
REGULATORY T-CELLS IN COLORECTAL CANCER PATIENTS K. Vasilieva
7. ACTIVITY TESTING OF DIFFERENTLY PRODUCED PREPARATIONS OF GDF-15 T. Hanso
Chairs: T. Frisan (SE), L. Conti (IT)
14.40-15.00 Challenges in the Development of an Academic CAR-T Cell Program
in Emerging Countries A. Madrigal (UK)
15.00-15.20 Lessons from pregnancy for immunomodulation in
cancer and autoimmunity J. Wischhusen (DE)
15.20-15.40 T cell therapy in melanoma Ε.M. Inderberg (NO)
15.40-16.00 Discussion
Chairs: C.N. Baxevanis (GR), Ε.M. Inderberg (NO)
16.20-16.50 Identification of T cell target antigens in
small cell lung cancer C. Gouttefangeas (DE)
16.50-17.20 Systemic immune response in pancreatic cancer - potential role
for immunotherapy L. Bojmar (SE)
17.20-17.50 Toll-like Receptor 2-Targeted Therapies Enhance Chemotherapy
and Immunotherapy Efficacy in Breast Cancer L. Conti (IT)
17.50-18.20 Discussion
Chairs: Κ. Dimitropoulos (GR), F. Koinis (GR)
18.30-18.50 Immunotherapy in urothelial carcinomas F. Koinis (GR)
18.50-19.10 Advances in immunotherapy in renal cell carcinoma P. Vlachostergios (GR)
19.10-19.30 Discussion
Chairs: S. Karagiannis (UK), J. Wischhusen (DE), I. Pateras (GR), T. Frisan (SE)
Chairs: C. Gouttefangeas (DE), J. Wischhusen (DE)
08.40-09.00 Decoding the Tumor Microenvironment: Analysis of
Multiple Biomarkers in Human Tissues Il. Nikas (CY)
09.00-09.20 CTCs pancreas - Circulating Tumor Cells (CTCs) and immune
checkpoints molecules; Clinical relevance and perspectives G. Kallergi (GR)
09.20-09.40 Emerging Immune Biomarkers in Prevalent Solid Tumors I. Pateras (GR)
09.40-10.00 Advancing cancer diagnosis and prognosis with
spatial transcriptomics and AI A. Giakountis (GR)
10.00-10.20 Discussion
Chairs: G. Kallergi (GR), I. Pateras (GR)
10.50-11.10 Allotypic variation in antigen presentation regulates
the immunopeptidome of cancer cells E. Stratikos (GR)
11.10-11.30 Design of monoclonal antibody therapies for solid tumours through
the study of patient immune responses S. Karagiannis (UK)
11.30-11.50 Discussion
Chair: A. Giakountis (GR), A. Xagara (GR)
1. WHOLE EXOME SEQUENCING OF A RARE SUBTYPE OF INVASIVE
LOBULAR CARCINOMA N. Koufopoulos
2. SPATIAL ANALYSIS AND PROGNOSTIC IMPACT OF TILs IN
OPERABLE NON-SMALL CELL LUNG CARCINOMAS K. Ntostoglou
3. IMMUNE-RELATED GENE SIGNATURES WITH PROGNOSTIC POTENTIAL IN
PATIENTS WITH HEAD AND NECK CANCER P. Batsaki
4. T-CELL IMMUNITY TOWARDS HER-2/neu IN PATIENTS WITH BREAST CANCER E. Mitsaki
Chairs: V. Georgoulias (GR), T. Frisan (SE)
Immunotherapy in breast cancer past present future - beyond triple negative? J. Bergh (SE)
Chairs: E. Stratikos (GR), S. Karagiannis (UK)
14.00-14.20 The role of T cells as biomarkers in cancer M. Goulielmaki (GR)
14.20-14.40 Dissecting the tumor microenvironment in early breast cancer:
clinical implications and novel insights A. Matikas (SE)
14.40-15.00 Targeting TNF Receptors for Tumor Therapy A. Beilhack (DE)
15.00-15.20 The Role of Epigenetic Modulation in Tumorigenesis? V. Anastasopoulou (GR)
15.20-15.40 Discussion
Chairs: V. Papadopoulos (GR), E. Zafeiriou (GR)
15.40-16.10 10 years of Immunotherapy in Melanoma A. Laskarakis (GR)
16.10-16.40 Immune Checkpoint Blockade in Melanoma - Past, Present and Future A. Selvan
Sponsored Lecture
16.40-17.00 Discussion
Chairs: A. Kotsakis (GR), K. Tsapakidis (GR)
17.15-17.45 Reinforcing therapeutic options for patients with NSCLC and PD-L1
positive expression without driver mutations I. Mountzios (GR)
Sponsored Lecture
17.45-18.15 Shaping the Future of resectable NSCLC:
Exploring the latest Therapeutic Strategies A. Bokas (GR)
Sponsored Lecture
18.15-18.45 Bridging the gap with dual immunotherapy in
patients with metastatic NSCLC and low PD-L1 expression D. Ziogas (GR)
Sponsored Lecture
18.45-19.00 Discussion
Chair: V. Georgoulias (GR), E. Saloustros (GR)
19.20-19.40 Novel therapeutic approaches in gynecological cancer M. Liontos (GR)
19.40-20.00 MTAP deleted cancers K. Leventakos (US)
Chair: A. Kotsakis (GR), V. Georgoulias (GR)
Pathology in the era of precision oncology P. Foukas (GR)
Chairs: S. Karagiannis (UK), J. Wischhusen (DE), I. Pateras (GR), T. Frisan (SE)
Chairs: G. Samaras (GR), F. Koinis (GR)
08.40-09.00 IO in cholangiocarcinoma G. Oikonomopoulos (GR)
09.00-09.20 IO in gastric and gastroesophageal carcinoma A. Stribakos (GR)
09.20-09.40 IO in colorectal carcinoma G. Papaxoinis (GR)
09.40-10.00 Discussion
Chairs: A. Kotsakis (GR), V. Papadopoulos (GR) Recent updates in resectable Locally Advanced Head and Neck cancer E. Sogka (GR)
Chairs: A. Kotsakis (GR), V. Papadopoulos (GR)
HLA-class-I expression loss in cancer and therapeutic restoration:
the role of Radiotherapy and Autophagy M. Koukourakis (GR)
Chairs: S. Karagiannis (UK), J. Wischhusen (DE), I. Pateras (GR), T. Frisan (SE)














